HFM information and reviews
HFM
96%
FXCC information and reviews
FXCC
92%
FxPro information and reviews
FxPro
89%
FBS information and reviews
FBS
88%
Vantage information and reviews
Vantage
85%
XM information and reviews
XM
82%

Stocks of companies working on COVID-19 vaccine


The spread of coronavirus COVID-19 has paralyzed social and economic activity in most countries of the world. Despite the fact that a number of countries are now preparing to ease social restrictions and restart the economy, many experts expect a second or even third wave of COVID-19 incidence. And the head of WHO believes that it will not be possible to stop the coronavirus without a vaccine.

The recovery of the economy and the value of many financial assets may directly depend on progress in COVID-19 vaccine development. Currently, more than 100 organizations are involved in the process, including several public companies in the pharmaceutical and biotechnology sectors. Only in March 2020, WHO registered about 500 clinical trials of a vaccine and treatments for a new disease.

But there is currently no clinically tested vaccine sample. In February 2020, WHO expected the appearance of a working vaccine no earlier than 18 months later.

The huge budgets and high involvement of pharmaceutical companies around the world give hope for a fast pace of vaccine development. Already in April 2020, according to the Milken Institute in the United States, about 100 candidates for vaccines were registered in the world. According to the institute, it’s convenient to track not only the vaccine development process, but also the methods of treating a new disease.

As of April 24, seven of the candidates submitted have been undergoing or have passed the first stage of clinical trials in the human body. As part of the first phase, safety for the person is checked mainly. To produce a working vaccine, candidates must go through another, most important, third stage of research. As a rule, tests in the framework of the third phase are much longer and more extensive.

According to the Milken Institute, one of the candidates developed by the Beijing Biotechnology Institute is already undergoing the second phase of testing. The US biotechnology vaccine Moderna, which received $483 million from the US government to speed up the development process, is undergoing the first phase of clinical trials. The second phase should begin in the 2nd quarter 2020. The first and second phases are planned to be completed in June 2020.

Despite the rapid start of vaccine development and methods of treating a new coronavirus disease, a number of studies show that the probability of a vaccine candidate for passing the second stage of a clinical trial can be about 18-30%. The third stage is already about 50% of the tested vaccines.

Moderna (MRNA)


This American biotech is now considered the top favorite among public companies in the development of COVID-19 vaccine. The company specializes in RNA biochemistry, most of the research is devoted to the study and development of vaccines. Moderna entered the IPO quite recently, at the end of 2018. Like most biotech companies listed on the stock exchange, MRNA remains unprofitable, both in terms of net profit and EBITDA. Over the past 12 months, EBITDA loss was $1.44 per share. Earnings per share does not show stable growing dynamics. The company is traded under the ticker MRNA.

Arcturus Therapeutics Holdings (ARCT)


Another public company developing a new vaccine is Arcturus Therapeutics. The first phase of the candidate’s trials should begin in the summer of 2020. The company received permission for clinical trials after a successful preclinical study.

ARCT has long gone to IPO, but still remains unprofitable, even at the EBITDA level. ARCT capitalization does not exceed $0.5 billion. The loss on EBITDA for 12 months amounted to $24 million. The company's revenue since 2016 does not show a stable result, and due to periodic additional issues per share, it has significantly decreased. The company is traded on the NASDAQ under the ticker symbol ARCT.

Inovio Pharmaceuticals (INO)


Another American biotech is developing a vaccine in collaboration with Beijing Advaccine Biotechnology. Companies began the first phase of clinical trials in April. Ends of phases I and II are expected by the end of summer 2020.

INO is a biotechnology company with small capitalization about $ 2billion. This Biotech became public even before the dot-com boom in 2000. The EBITDA loss over the past 12 months amounted to $105 million. The company's revenue over the past three years has been sharply and consistently declining. INO is overloaded with high debt. Debt / Eq is 29x. Despite the extremely negative financial results, the company's shares over the past two months have grown by tens of percent amid news about the development of the vaccine. The company’s stocks are traded on NASDAQ under the ticker symbol INO.

Applied DNA Science (APDN)


The company’s shares have been traded on NASDAQ since 2013. During this time, its capitalization dropped to $22 million. Shares are currently traded near historical lows. The company has been unprofitable at the EBITDA level for the past three years. Earnings per share are gradually decreasing. Debt load ratio is relatively low, Debt / Eq is 0.21x.

Shares of APDN have shown revival in recent weeks amid reports of vaccine development. The company works in consortium with Takis and Evvivax. Preclinical trials should be completed soon, clinical trials are scheduled for autumn 2020, but permission for them has not yet been obtained. Obtaining an appropriate certificate can significantly affect stock quotes.

Dynavax (DVAX)


This biotech is working on a vaccine with several other companies. Together with the Chinese Sinovax, Dynavax is scheduled to begin phase I and II clinical trials soon. Only preclinical studies of vaccines under development are underway with other manufacturers.

DVAX is a small biotech with a capitalization of $285 million. EBITDA loss over the past 12 months amounted to $114 million. The company's earnings per share are growing at an unstable pace. The stock is traded on Nasdaq.

Novavax (NVAX)


Novavax is a relatively large and long-standing biotechnology company with a capitalization of about $1 billion. EBITDA loss over the past 12 months amounted to $114 million. The company's earnings per share do not show stable growth. Given negative equity and negative EBITDA, the company's debt burden is high.

NVAX, together with Emergent BioSolutions, plans to begin clinical trials of the vaccine. The company's shares over the past few weeks have risen significantly amid the announcement of a vaccine development. The stocks are traded on the NASDAQ under the NVAX ticker.

Pfizer (PFE)


Pfizer is an international pharmaceutical giant with a capitalization of $209 billion. Pfizer announced the development of a vaccine in conjunction with the German BioNTech. The company began the first phase of clinical trials in late April. Unlike most of the biotechs listed here, Pfizer is a profitable company with consistent earnings growth per share. EBITDA over the past 12 months increased by 36%, earnings per share by 53% - to $2.48. Not taking into account the impact of participation in the development of the vaccine against COVID-19, analysts expect growth in earnings per share by 5-6% in 2020. The stock is traded on NASDAQ Exchange under the ticker symbol PFE.

Who else plans to start clinical trials


In addition to the above American biotechnology and pharmaceutical companies, there are several European public companies that are also participating in the vaccine development sprint. These are, for example, the Swedish ISR Immune System Regulation (ISR) and the French Sanofi (SNY). Shares of these companies are traded on European exchanges or in the form of receipts on the NASDAQ.

In addition to private and public companies, a large number of institutes and public institutions are involved in the development of vaccines at different phases. There are the Beijing and Wuhan Bioproducts Institutes, the Shenzhen Gene-Immune Medical Institute, a consortium of European medical institutes in cooperation with AdaptVac, Merk and others among them.

Summary


Despite the fact that a very large number of private companies and government institutions have joined COVID-19 vaccine development race, only a few are embarking on a very important barrier phase II clinical trial.

As practice shows, no more than a third of the declared candidates pass in the III phase of testing, which lasts much longer than the first two. In connection with this state of affairs, the dates for the creation of a working and tested vaccine announced by WHO no longer seem pessimistic.

The development of a vaccine from COVID-19 is a strategic priority of the states, and a large amount of funds is allocated for its creation. Thanks to this, many small farms and biotech companies have joined the development.

Most of the public biotechnologists who have announced an attempt to develop a vaccine are unprofitable at the EBITDA level. The exception is the global pharmaceutical company Pfizer. Quotations of its shares have already significantly responded to positive and promising news and may grow more as the safety and effectiveness of the vaccine candidate are confirmed.

However, disappointing clinical trial statistics should be considered. Only 18-30% of candidates will be able to pass the second phase of testing. In case of failure, most likely, the shares’ price of such companies will rapidly drop.

Bill Gates: innovation is needed in 5 areas to get life back on track


According to Gates, a “semi-normal” world can be expected over the next two months: “People can go out, but not so often, to crowded places,” he writes. The basic principle should be to allow activities that are of great benefit to the economy or the well-being of people, but pose a small risk of infection, the tech billionaire believes.

Most of the story will go on


In his thoughts, Gates says that the world so far has survived only a third of COVID-19 pandemic consequences. Even when governments open enterprises and companies, the situation will not be standard. Behavior of people will change, there will be a natural aversion to the fact that you can suddenly become infected. Therefore, he predicts: “There will not be a large crowd at airports. Sporting events will take place at empty stadiums. And the global economy will be depressed because demand will be low.”

When life returns to normal


This will only happen after most of the population has been vaccinated, and this may take some time. Bill Gates hopes that the vaccine will be launched into mass production by the second half of 2021. If this happens, it will be a historic achievement: the shortest path in history when mankind moved from recognizing a new disease to immunization against it.

In a CNBC interview, Gates emphasized that the world must promote a variety of treatments, vaccines, testing, contact tracing, and test its own virus detection policies.

Microsoft leader believes innovation is needed in 5 areas.

Author: Kate Solano for Forex-Ratings.com

RELATED

Bitcoin Investment: A Guide To Trade Bitcoin

As you may already know, cryptocurrency, especially bitcoin, is the most traded financial instruments in recent history. Bitcoin is a popular digital currency among...

Soulbound Tokens (SBTs): Pioneering Digital Identity in the Blockchain Era

Soulbound tokens (SBTs) represent a groundbreaking concept in blockchain technology, championed by Ethereum co-founder Vitalik Buterin and inspired by mechanics from the popular fantasy game...

Bonds in 2023: Deep Dive into 7 Essential Bond Types for Investors

In the world of investment, bonds stand as one of the cornerstones, allowing entities, whether corporate or governmental, to secure funds over an agreed duration...

What is an NFT?

It is fair to say that 2021 was the year of NFT, Ethereum’s enfant terrible. Non-fungible tokens invaded the world of digital currencies to become...

What Is Cosmos Crypto?

Scalability and interoperability have been two significant problems for the blockchain world. There are a handful of options for interoperable blockchain networks...

Libertex: Crypto bears getting ready to hibernate

After a short hiatus, the cryptocurrency market is back in the spotlight once again. Just a matter of weeks ago, there was talk of burst bubbles, lost fortunes and even a long...

FXOpen Forex Partnership Program

We offer our Forex partnership program to traders, Forex brokers, and website owners who publish information about fiat and crypto-currency trading...

Top Tech Trends of the Future for Trading

Tech development impacts our daily lives as well as traders’ profits. Technologies change rapidly, creating new opportunities in everyday routine and the stock market...

What is Leverage Trading in Crypto?

Leverage trading, also known as margin trading, allows you to significantly magnify your profits in the markets. However, bear in mind that leverage...

What Is Crypto Lending and How Does It Work?

Crypto lending allows cryptocurrency owners to lend their coins to borrowers. They will gain some profit as a result of this. It's more like putting money in a savings account...

Monero: New All-Time High Coming?

Monero has seen significant gains over the past few months, more than doubling in price. However, there is room for growth - at the very least, to its all-time high of $495.84...

What is Leverage in Forex: A Beginner’s guide

Leverage can be an essential feature to use, especially when trading foreign currencies via Contract of Difference (“CFD”). Leverage allows you to open larger positions with relatively little capital...

Trading Like A CFO - Planning

We already went over the similarities between trading and financial management. Now we are going to get a little deeper into each...

Investing vs trading cryptocurrency: What's right for you?

People often mistake investing and trading for the same thing. However, they are very different and each has its own characteristics when it comes to crypto...

How to avoid analysts' mistakes?

We often hear about an undervalued asset, an unfair exchange rate, or an overvalued dividend forecast. In my opinion, such "expert" statements...

How to make money on meme stock?

Meme stocks are shares that gained popularity and achieved a cult-like following on social media. As a result, private investors in online communities can create hype and influence the price of individual shares...

Which Citizenship by Investment Programs are Crypto-Friendly?

With the evolution of the digital era, the crypto industry has taken the world by storm. In most countries, digital assets are considered a commodity rather than currency...

Which US companies can increase dividends despite COVID-19

The US economy has entered a deep recession since the beginning of the COVID-10 pandemic, and American corporations along with it. Dividends are in jeopardy...

Forex vs Stocks: Differences, Similarities, and Which to Choose

The forex markets and the stock markets are two popular choices for investors and traders seeking to capitalise on market opportunities. While both markets offer potential for returns...

VeChain: Is It on the Verge of Massive Growth?

Asia continues to be at the forefront of blockchain development, and VeChain is one of the brightest crypto projects in the region. There are different opinions...

FP Markets information and reviews
FP Markets
81%
RoboForex information and reviews
RoboForex
77%
IronFX information and reviews
IronFX
77%
T4Trade information and reviews
T4Trade
76%
Exness information and reviews
Exness
76%
Just2Trade information and reviews
Just2Trade
76%

© 2006-2025 Forex-Ratings.com

The usage of this website constitutes acceptance of the following legal information.
Any contracts of financial instruments offered to conclude bear high risks and may result in the full loss of the deposited funds. Prior to making transactions one should get acquainted with the risks to which they relate. All the information featured on the website (reviews, brokers' news, comments, analysis, quotes, forecasts or other information materials provided by Forex Ratings, as well as information provided by the partners), including graphical information about the forex companies, brokers and dealing desks, is intended solely for informational purposes, is not a means of advertising them, and doesn't imply direct instructions for investing. Forex Ratings shall not be liable for any loss, including unlimited loss of funds, which may arise directly or indirectly from the usage of this information. The editorial staff of the website does not bear any responsibility whatsoever for the content of the comments or reviews made by the site users about the forex companies. The entire responsibility for the contents rests with the commentators. Reprint of the materials is available only with the permission of the editorial staff.
We use cookies to improve your experience and to make your stay with us more comfortable. By using Forex-Ratings.com website you agree to the cookies policy.